中国医学科学院肿瘤医院胸外科创建于1958年，是我国第一个胸部肿瘤外科，现为国家重点临床专科，在复旦大学医院管理研究所发布的“中国医院专科声誉排行榜”上连续12年位列全国胸外科综合排行榜第一名，年手术量达5000例，其中胸部肿瘤数量居全国之首。

      中国医学科学院肿瘤医院胸外科实验室由我国胸部肿瘤领军专家赫捷院士一手创办，具有20年的研究历史，现有院士1名（课题组PI赫捷院士），研究员1名，副研究员2名，工作人员6名，在读博士研究生及博士后流动人员30余名，北京协和医学院临床医学（八年制）工作人员轮转进行课题研究10余名。实验室具有先进完善的分子生物学实验、生物信息学技术平台及国内最大的肺癌标本组织库。

1. 国家重点研发计划项目, 2021YFF1201300, 基于跨尺度多模态生物医学大数据的肿瘤智能诊疗共性关键技术研究 , 2022/01-2024/12, 4200万元，在研，骨干参与

2. 中国医学科学院（重大协同创新），2021-I2M-1-012，重点疾病防治集成性研究，2021/10-2025/12，5200万元，在研，骨干参与

3. 国家自然科学基金面上项目，81972196，多原发肺癌中Pim-1胚系突变的功能及作用机制研究，2020/01-2023/12，55万元，结题，主持

4. 国家重点研发计划项目，2018YFC1312100，恶性肿瘤规范化早诊早治关键技术集成及应用体系建设研究，2018/08-2020/12，4862万元，结题，子课题负责人

5. 国家自然科学基金青年项目，81402476，融合基因MSH3-RASGRF2 在MTX诱导DHFR扩增耐药中的功能，2015/01-2017/12，23万元，结题，主持

6. 国家级中国博士后基金(一等)，2011M500060，卵巢癌中断裂融合基因的筛选和鉴定，2011/12-2013/12，5万元，结题，主持

7. 黑龙江省博士后基金，LRB-87864，卵巢癌中断裂融合基因的筛选和鉴定，2010/12-2012/12，4万元，结题，主持

1. 国家重点研发计划项目, 2021YFF1201300, 基于跨尺度多模态生物医学大数据的肿瘤智能诊疗共性关键技术研究 , 2022/01-2024/12, 4200万元，在研，骨干参与

2. 中国医学科学院（重大协同创新），2021-I2M-1-012，重点疾病防治集成性研究，2021/10-2025/12，5200万元，在研，骨干参与

3. 国家自然科学基金面上项目，81972196，多原发肺癌中Pim-1胚系突变的功能及作用机制研究，2020/01-2023/12，55万元，结题，主持

4. 国家重点研发计划项目，2018YFC1312100，恶性肿瘤规范化早诊早治关键技术集成及应用体系建设研究，2018/08-2020/12，4862万元，结题，子课题负责人

5. 国家自然科学基金青年项目，81402476，融合基因MSH3-RASGRF2 在MTX诱导DHFR扩增耐药中的功能，2015/01-2017/12，23万元，结题，主持

6. 国家级中国博士后基金(一等)，2011M500060，卵巢癌中断裂融合基因的筛选和鉴定，2011/12-2013/12，5万元，结题，主持

7. 黑龙江省博士后基金，LRB-87864，卵巢癌中断裂融合基因的筛选和鉴定，2010/12-2012/12，4万元，结题，主持

科研论文：

1.  Ziqin Deng#, Tao Fan#, Chu Xiao, HeTian, Yujia Zheng, Chunxiang Li*, Jie He*. TGF-β signaling in health,disease, and therapeutics. Signal Transduct Target Ther. 2024;9(1):61. doi:10.1038/s41392-024-01764-w. IF=39.3

2. Zhenlin Yang#, Bolun Zhou#, Wei Guo#, Yue Peng#, HeTian, Jiachen Xu, Shuaibo Wang, Xiaowei Chen, Bin Hu, Chengming Liu, ZhijieWang, Chunxiang Li*, ShugengGao*, Jie He*. Genomic characteristics and immune landscape of super multipleprimary lung cancer. EBioMedicine. 2024 Feb 15:101:105019. doi:10.1016/j.ebiom.2024.105019. IF=11.1

3.  Tao Fan#, ChuXiao#, Hengchang Liu, Yu Liu, Liyu Wang, He Tian, ChunxiangLi*, Jie He*. CXXC finger protein 1 (CFP1) bridges thereshaping of genomic H3K4me3 signature to the advancement of lungadenocarcinoma. Signal Transduct Target Ther. 2023;8(1):369. doi:10.1038/s41392-023-01612-3. IF=39.3

4.  Yujia Zheng#,Hao Zhang#, Chu Xiao, Ziqin Deng, Tao Fan, Bo Zheng, ChunxiangLi*, Jie He*. KLF12 overcomes anti-PD-1 resistance byreducing galectin-1 in cancer cells. J Immunother Cancer. 2023;11(8):e007286.doi: 10.1136/jitc-2023-007286. IF=10.9

5.  Chu Xiao, TaoFan, Yujia Zheng, He Tian, Ziqin Deng, Jingjing Liu, ChunxiangLi*, Jie He*. H3K4 trimethylation regulates cancerimmunity: a promising therapeutic target in combination with immunotherapy. J Immunother Cancer. 2023;11(8):e005693. doi:10.1136/jitc-2022-005693. IF=10.9

6.  TaoFan, Chu Xiao, Shan Muhammad, Chunxiang Li*, Jie He*. BATFreprograms the tumor immune status. Med. 2023;4(1):10-12.doi:10.1016/j.medj.2022.12.004. IF=17.0

7.  Tao Fan#, Mingchuang Zhu#, Shan Muhammad, Chu Xiao, Shuofeng Li, He Tian, Yu Liu, Liyan Xue, Bo Zheng, Chunxiang Li*, Jie He*. H3K4me3-related lncRNAssignature and comprehensive analysis of H3K4me3 regulating tumor immunity inlung adenocarcinoma. Respir Res.2023;24(1):122.doi:10.1186/s12931-023-02418-1. IF=5.8

8.  He Tian, Yalong Wang, Zhenlin Yang, Ping Chen, Jiachen Xu, Yanhua Tian, Tao Fan, Chu Xiao, Guangyu Bai, Lin Li, Bo Zheng, Chunxiang Li*, Jie He*. Genetic trajectory and clonalevolution of multiple primary lung cancer with lymph node metastasis cancergene therapy. Cancer Gene Ther. 2023 ;30(3):507-520. doi:10.1038/s41417-022-00572-0. IF=6.4

9.  He Tian#, Guangyu Bai#, Zhenlin Yang#, Ping Chen, Jiachen Xu, Tiejun Liu, Tao Fan, Bingning Wang, Chu Xiao, Chunxiang Li*, Shugeng Gao*, Jie He*. Multiple primary lung cancer:Updates of clinical management and genomic features. FrontOncol. 2023;13:1034752. doi: 10.3389/fonc.2023.1034752. eCollection. IF=4.7

10. Tao Fan#,Shuofeng Li#, Chu Xiao#, He Tian, Yujia Zheng, Yu Liu, Chunxiang Li*,Jie He*.CCL20 promotes lung adenocarcinoma progression bydriving epithelial-mesenchymal transition. Int J Biol Sci. 2022 Jun27;18(11):4275-4288. doi: 10.7150/ijbs.73275. IF=10.750

11. Zheng Zhou#,Yujia Zheng#, Shaobo Mo#, Shuofeng Li, Xinlei Zheng, Ran Wei, Tao Fan, TianliChen, Chu Xiao, Chunxiang Li*, Jie He*. Establishmentand Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature inPan-cancer Patients: A Multicenter, Real-world Study. Int J Biol Sci. 2022 May21;18(9):3762-3776. doi: 10.7150/ijbs.71385. IF=10.750

12. Xiao Chu#,Tian He, Zheng Yujia, Yang Zhenglin, Li Shuofeng, Fan Tao, Xu Jianing, BaiGuangyu, Liu J, Deng Ziqin, Li Chunxiang*, He Jie*. Glycolysis in tumormicroenvironment as a target to improve cancer immunotherapy. Front Cell DevBiol. 2022 Sep 19;10:1013885. doi: 10.3389/fcell.2022.1013885. IF=6.081

13. Zheng Yujia#,Zhou Zheng, Wei Ran, Xiao Chu, Zhang Hao, Fan Tao, Li Chunxiang*, HeJie*. The RNA-binding protein PCBP1 represses lung adenocarcinoma progressionby stabilizing DKK1 mRNA and subsequently downregulating β-catenin. J TranslMed. 2022 Jul 30;20(1):343. doi: 10.1186/s12967-022-03552-y. IF=8.448

14. Yu Liu#,Chunxiang Li#*, Lingling Fang, Hengchang Liu, He Tian, Yujia Zheng, TaoFan, Jie He*. Lipid metabolism-related lncRNA SLC25A21-AS1 promotes theprogression of oesophageal squamous cell carcinoma by regulating the NPM1/c-Mycaxis and SLC25A21 expression. Clin Transl Med. 2022 Jun;12(6):e944. doi:10.1002/ctm2.944. IF=8.554

15. Zhenlin Yang#, He Tian#, Lin Li#, Chao Li, Jiachen Xu, Fenglong Bie, Ying Chen, Yanhua Tian, Guangyu Bai, Yue Peng, Junhui Yang, Tao Fan, Chu Xiao, Wenchao Liu, Lei Liu, Renda Li, Sijin Sun, Bo Zheng, Fengwei Tan, Jianming Ying, Chunxiang Li*, Shugeng Gao*, Jie He*. PSCsubtyping based on TTF-1 and p40 expression reveals distinct molecularcharacteristics and therapeutic strategies. Int J Cancer. 2022 Sep1;151(5):717-729. doi: 10.1002/ijc.34137. IF=7.316

16. Tao Fan, Yu Liu, Hengchang Liu, LiyuWang, He Tian, Yujia Zheng, Bo Zheng, Liyan Xue, Chunxiang Li*, Jie He*.Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristicsin Lung Adenocarcinoma. Front Oncol. 2022 Mar 22;12:828814. doi:10.3389/fonc.2022.828814. IF=6.244

17. ZhenlinYang#, He Tian#, Fenglong Bie#, Jiachen Xu, Zheng Zhou, Junhui Yang, Renda Li,Jie Wang, Chunxiang Li*, Shugeng Gao*, Jie He*. ERAP2 Is Associated WithImmune Infiltration and Predicts Favorable Prognosis in SqCLC. Front Immunol.2021 Dec 21;12:788985. doi: 10.3389/fimmu.2021.788985. IF=7.561

18. TaoFan#,Chunxiang Li*, Jie He*. Prognostic value of immune-related genes andcomparative analysis of immune cell infiltration in lung adenocarcinoma: sexdifferences. Biol Sex Differ. 2021 Dec 4;12(1):64. doi:10.1186/s13293-021-00406-y. IF=5.027

19. Liu Yu#,Wang Liyu#, Fang Lingling#, Liu Hengchang, Tian He, Zheng Yujia, Fan Tao, LiChunxiang*, He Jie*.A Multi-Center Validated SubtypingModel of Esophageal Cancer Based on Three Metabolism-Related Genes. FrontOncol. 2021 Oct 25;11:772145. doi: 10.3389/fonc.2021.772145. IF=6.244

20. ChuXiao#, Tao Fan#, Tian He, Yujia Zheng, Zheng Zhou, Shuofeng Li, ChunxiangLi*, He Jie*. H3K36 trimethylation-mediated biological functions in cancer.Clin Epigenetics. 2021 Oct 29;13(1):199. doi: 10.1186/s13148-021-01187-2. IF=6.551

21. TaoFan#, Yu Liu, Hengchang Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Zheng, LiyanXue, Fengwei Tan, Qi Xue, Shungeng Gao, Chunxiang Li*, Jie He*.Comprehensive analysis of a chemokine- and chemokine receptor family-basedsignature for patients with lung adenocarcinoma. Cancer Immunol Immunother.2021 Dec;70(12):3651-3667. doi: 10.1007/s00262-021-02944-1. IF=6.968

22. TaoFan#, Zhiliang Lu#, Yu Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Zheng, LiyanXue, Fengwei Tan, Qi Xue, Shugeng Gao, Chunxiang Li*, Jie He*. A NovelImmune-Related Seventeen-Gene Signature for Predicting Early Stage LungSquamous Cell Carcinoma Prognosis. Front Immunol. 2021 Jun 11;12:665407. doi:10.3389/fimmu.2021.665407. IF=7.561

23. Chunxiang Li#, Hengchang Liu, Ran Wei, Zheng Liu, Haipeng Chen, Xu Guan, Zhixun Zhao, Xishan Wang, Zheng Jiang*.LncRNA EGOT/miR-211-5p Affected Radiosensitivity of Rectal Cancer byCompetitively Regulating ErbB4. Onco Targets Ther. 2021 Apr 28;14:2867-2878.doi: 10.2147/OTT.S256989. IF=4.147

24. ChunxiangLi#,Yalong Wang#, Kai Su, Yu Liu, Liyu Wang, Bo Zheng, Na Yan, Dawei Yuan, YanxiangZhang, Liyan Xue, Shugeng Gao, Jie He*. Presentation of EGFR mutations in 162 family probands with multiple primary lungcancer. Transl Lung Cancer Res. 2021 Apr;10(4):1734-1746. doi:10.21037/tlcr-20-1001. IF=6.498

25. YujiaZheng#, He Tian#, Zheng Zhou, Chu Xiao, Hengchang Liu, Yu Liu, Liyu Wang, TaoFan, Bo Zheng, Fengwei Tan, Qi Xue, Gengshu Gao, ChunxiangLi*, Jie He*. A Novel Immune-Related Prognostic Modelfor Response to Immunotherapy and Survival in Patients With LungAdenocarcinoma. Front Cell Dev Biol. 2021 Mar 19;9:651406. doi:10.3389/fcell.2021.651406. IF=6.684

26. HeTian#, Liyu Wang, Yu Liu, Yalong Wang, Yujia Zheng, Tao Fan, Bo Zheng, FengweiTan, Qi Xue, Shugeng Gao, Chunxiang Li*, JieHe*. Bioinformatics Analyses Reveals a Comprehensive Landscape of CXC ChemokineFamily Functions in Non-Small Cell Lung Cancer. Biomed Res Int. 2021 Jan 27;2021:6686158. doi:10.1155/2021/6686158. IF=3.411

27. LiyuWang#, Yu Liu, Hengchang Liu, He Tian, Yalong Wang, Guochao Zhang, YuanyuanLei, Liyan Xue, Bo Zheng, Fengwei Tan, Qi Xue, Shugeng Gao, ChunxiangLi*, Jie He*. The therapeutic significance of the novelphotodynamic material TPE-IQ-2O in tumors. Aging (Albany NY). 2020 Dec19;13(1):1383-1409. doi: 10.18632/aging.202355. IF=5.682

28. Tao Fan#, MingchuangZhu, Liyu Wang, Yu Liu, He Tian, Yujia Zheng, FengweiTan, Nan Sun, Chunxiang Li*, JieHe*. Immune profile of the tumor microenvironment and the identification of afour-gene signature for lung adenocarcinoma. Aging (Albany NY). 2020 Dec9;13(2):2397-2417. doi: 10.18632/aging.202269. IF=5.682

29. ChunxiangLi#, JichuanQuan, Ran Wei, Zhixun Zhao, Xu Guan, Zheng Liu, ShuangmeiZou, Xishan Wang, Zheng Jiang*. Leptin Overexpression as a PoorPrognostic Factor for Colorectal Cancer.Biomed Res Int. 2020 Jun 04;2020:7532514. doi: 10.1155/2020/7532514. IF=3.411

30. Yu Liu#, LiyuWang, Hengchang Liu, ChunxiangLi*, Jie He*. The Prognostic Significance of Metabolic Syndrome and aRelated Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma. FrontOncol. 2020 Feb 18;10:61. doi: 10.3389/fonc.2020.00061. IF=4.848

31.  ChunxiangLi#,Xiaofu Li, Linfeng Wu, Zheng Jiang*. Elevated AQP1 Expression Is Associatedwith Unfavorable Oncologic Outcome in Patients with HilarCholangiocarcinoma. Technol Cancer Res Treat, 2017, 16(4):421-427.

32.  ChunxiangLi#,Sanjun Cai, Xishan Wang, Zheng Jiang*. Hypomethylation-associated up-regulationof TCF3 expression and recurrence in stage II and III colorectal cancer. PLoSOne,2014, 9(11):e112005.

33.  ChunxiangLi#,Zhongcheng Shi, Liqiu Zhang, Yun Huang, An Liu, Yan Jin, Yang Yu, Jing Bai,Dieyan Chen, Gendron C, Xinghan Liu, Songbin Fu*. Dynamic changes ofterritories 17 and18 during EBV-infection of human lymphocytes, Mol Biol Rep,2010, 37(5):2347-54.

34.  ChunxiangLi#,Zheng Jiang, Xinghan Liu*. Biochemical mechanism of gallium on prevention offatal cage-layer osteoporosis, Biol Trace Elem Res, 2010, 134(2):195-202.

35.  Zheng Jiang#, Chunxiang Li#, Ye Xu, Sanjun Cai,Xishan Wang*. Associations between XPD polymorphisms and risk of breast cancer:a meta-analysis, Breast Cancer Res Treat, 2010, 123(1): 203-12.

36.  Zheng Jiang#, Chunxiang Li#, Xishan Wang*.GlutathioneS-transferase M1 polymorphism and bladder cancer risk: a meta-analysisinvolving 33 studies. Exp Biol Med (Maywood), 2011, 236(6):723-8.

37.  Zheng Jiang#, Chunxiang Li#, Fuyuan Li, Xishan Wang*.EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer PatientsTreated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis,PLoS ONE,8(2), e56205, 2013.

38.  Mengdi Cai#, Huishu Zhang#, LiqingHou#, Wei Gao, Ying Song, Xiaobo Cui, ChunxiangLi, Rongwei Guan, Jinfa Ma, Xu Wang, Yue Han, Yafan Lv, Feng Chen, PingWang, Xiangning Meng*, Songbin Fu*. Inhibiting homologous recombinationdecreases extrachromosomal amplification but has no effect on intrachromosomalamplification in methotrexate-resistant colon cancer cells, Int J Cancer,2019,144(5): 1037–1048

39.  Zheng Jiang#, ChunxiangLi, Zhixun Zhao, Zheng Liu, Xu Guan, Ming Yang, Xiaofu Li, Dawei Yuan, Songbo Qiu, XishanWang*.Abnormal Liver Function Induced by Space-Occupying LesionsIs Associated with Unfavorable Oncologic Outcome in Patients with Colorectal Cancer LiverMetastases. BiomedRes Int. 2018;2018:9321270.

40. Xiangning Meng#, Xiuying Qi#,Huanhuan Guo#, Mengdi Cai, Chunxiang Li,Jing Zhu, Feng Chen, Huan Guo, Jie Li, Yuzhen Zhao, Peng Liu, Xueyuan Jia,Jingcui Yu, Chunyu Zhang, Wenjing Sun, Yang Yu, Yan Jin, Jing Bai, MingrongWang, Jesusa Rosales, Ki-Young Lee,Songbin Fu*. Novel role for non-homologous endjoining in the formation of double minutes in methotrexate-resistant coloncancer cells. J Med Genet, 2015, 52(2):135-44.

41. Jiajie Hao, Zhizhou Shi, ZhixinZhao, Yu Zhang, Ting Gong, Chunxiang Li,Ting Zhan, Yan Cai, Jintang Dong, Songbin Fu, Qimin Zhan, Mingrong Wang*. Characterizationof genetic rearrangements in esophageal squamous carcinoma cell lines by acombination of M-FISH and array-CGH: further confirmation of some split genomicregions in primary tumors. BMC Cancer. 2012;12:367.

42. Wei Ji, Zehua Bian, Yang Yu, ChaoYuan, Yang Liu, Lisa Yu, Chunxiang Li,Jing Zhu, Xueyuan Jia, Rongwei Guan, Chunyu Zhang, Xiangning Meng, Yan Jin,Jing Bai, Jingcui Yu, Ki-Young Lee, Wenjing Sun*, Songbin Fu*. Expulsionof micronuclei containing amplified genes contributes to a decrease in doubleminute chromosomes from malignant tumor cells. Int J Cancer. 2014;134(6):1279-88.

43. Zheng Jiang, Chunxiang Li, Xiaohui Qiu, Ye Xu, Xishan Wang, Sanjun Cai*. Analysisof factors associated with prognosis after colorectal cancer resection in 174Chinese elderly patients. J Gastrointest Surg, 15(4), 644-51, 2011.

44. Fuyuan Li, Chunxiang Li, Zheng Jiang, Ning Ma, Xu Gao*. XRCC3 T241Mpolymorphism and bladder cancer risk: a meta-analysis. Urology, 77(2), 511e1-5,2011.

45. Zheng Jiang, Chunxiang Li, Ye Xu, Sanjun Cai*, A meta-analysis on XRCC1 andXRCC3 polymorphisms and colorectal cancer risk. Int J Colorectal Dis, 25(2),169-80, 2010.

46. Jie Wu, Xuefeng Ren, XuelongZhang, Chunxiang Li, Yuzhen Li,Hongyu Ma, Yucheng Zhou, Yan Jin, Feng Chen, Jing Bai, Songbin Fu*, Thevascular endothelial growth factor +405 G/C polymorphism in psoriasis.JDermatol Sci, 57(1), 62-3, 2010.

发明专利：

1. 赫捷, 李春香, 刘宇. LncRNA SLC25A21-AS1在作为食管癌标志物中的应用，2023，ZL202110924327.8

2. 王锡山, 姜争, 李春香等. 用于预测直肠癌局部切除手术后复发风险的组合物、微阵列和计算机系统，2022，ZL201811534784.0

3. 姜争, 王锡山, 李春香等. 一种II期结直肠癌患者分类方法、介质、装置和预后系统. 申请号 202311165142.9

4. 赫捷, 李春香, 范涛. CFP1基因在制备用于治疗或检测肺腺癌的产品中的应用. 申请号2023102363013

5. 赫捷, 李春香, 范涛. SLAMF9在肿瘤免疫治疗中的应用. 申请号202211441431.2

6. 孟祥宁, 蔡梦迪, 李春香等. BRCA1蛋白在制备逆转肿瘤细胞对MTX耐药性的药物中的应用. 2015年.ZL2015103192652

7. 傅松滨, 孟祥宁, 朱静, 李春香等. DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用. 2014年.ZL2013102560889